EMA Validates PTC Therapeutics’ Submission for New Nonsense Mutation Cystic Fibrosis Indication for Translarna (Ataluren)
Cystic Fibrosis, News
The European Medicines Agency (EMA) recently accepted a submission of variation for a new indication from PTC Therapeutics regarding Translarna (ataluren) for nonsense mutation cystic fibrosis (nmCF), which would allow the drug ... Read more